November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

Medicaid Policy Changes Linked to Sharp Drop in GLP-1 Use for Weight Loss

🏥 Public Health 2 min read 👁 3

A University of Pittsburgh study in JAMA found an estimated 84% relative drop in Medicaid prescriptions for weight-loss GLP-1 medications after four states ended coverage in early 2026.

Medicaid Policy Changes Linked to Sharp Drop in GLP-1 Use for Weight Loss🏥Public Health

Photo: Medical Xpress

Key points

  • Prescription fills for weight-loss GLP-1s fell by an estimated 84% relative to control states after four state Medicaid programs ended coverage on Jan. 1, 2026.
  • Pennsylvania saw the largest prescription drop at 95.5%, with researchers estimating up to 526,600 total beneficiaries were affected across the four states.
  • The observational JAMA study tracked prescription data from 2022 to 2026 but could not evaluate direct clinical outcomes or private payments.

State coverage decisions can rapidly alter access to high-demand medications, according to a University of Pittsburgh study published in JAMA. Researchers found that when four states terminated Medicaid coverage for GLP-1 drugs prescribed for weight management on Jan. 1, 2026, quarterly prescription fills dropped by approximately 84% relative to states that maintained coverage.

The observational study analyzed Medicaid prescription data across all 50 states and Washington, D.C., from January 2022 through March 2026. In the four states that withdrew coverage—California, New Hampshire, Pennsylvania, and South Carolina—prescriptions for weight-loss GLP-1 medications fell from 2,914 to 421 per 100,000 beneficiaries between the final quarter of 2025 and the first quarter of 2026. Pennsylvania experienced the largest decrease at 95.5%, followed by New Hampshire (88%), California (75.2%), and South Carolina (60.8%). Researchers estimate that between 175,500 and 526,600 fewer Medicaid recipients filled these prescriptions after coverage ended.

Policy Rules and Study Limitations

While federal law generally requires Medicaid programs to cover most outpatient prescription drugs, states are permitted to exclude medications used specifically for weight loss. Between early 2022 and early 2026, quarterly weight-loss GLP-1 prescriptions nationwide grew by 5,858%, driven primarily by the 17 state Medicaid programs that chose to cover them. The researchers observed no statistically significant shift toward diabetes-approved GLP-1 formulations in the states that ended weight-loss coverage.

The study authors highlighted several limitations, noting that the dataset tracked prescription reimbursements rather than individual patients. Consequently, researchers could not verify whether patients paid out-of-pocket, accessed drugs through other covered indications like sleep apnea, or experienced changes in clinical health. What to know: Stopping GLP-1 medications abruptly can increase the risk of weight regain and related health issues. Patients affected by coverage changes should consult a healthcare professional before altering their treatment plans.

Source Medical Xpress — medicalxpress.com/news/2026-11-medicaid-coverage-weight-loss-drugs.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.